Yield10 Bioscience (Yield10 Bioscience) EPS (Basic)

: $-2.08 (TTM As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

Yield10 Bioscience's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $-0.27. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.08.

Yield10 Bioscience's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.27. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.08.

Yield10 Bioscience's EPS without NRI for the three months ended in Dec. 2023 was $-0.27. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -2.08.

During the past 3 years, the average EPS without NRI Growth Rate was 23.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 47.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 51.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Yield10 Bioscience's highest 3-Year average EPS without NRI Growth Rate was 68.50% per year. The lowest was -4.50% per year. And the median was 23.80% per year.

Yield10 Bioscience EPS (Basic) Historical Data

The historical data trend for Yield10 Bioscience's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yield10 Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

-35.50

-4.30

-2.33

-2.76

-1.82

Yield10 Bioscience Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)																-0.67	-0.76	-0.64	-0.41	-0.27

Yield10 Bioscience EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Yield10 Bioscience's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-14.455	-	0)	/	7.946
	=	-1.82

Yield10 Bioscience's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-3.266	-	0)	/	12.032
	=	-0.27

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.08

Yield10 Bioscience (NAS:YTEN) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Yield10 Bioscience EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Yield10 Bioscience's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Yield10 Bioscience (Yield10 Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Yield10 Bioscience Inc (NAS:YTEN) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

M6X3:Germany

Address

19 Presidential Way, Woburn, MA, USA, 01801

Website

https://www.yield10bio.com

Yield10 Bioscience Inc is an agricultural bioscience company. It focuses on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. The company uses two proprietary advanced biotechnology trait gene discovery platforms to improve fundamental crop yield through enhanced photosynthetic carbon capture and increased carbon utilization efficiency to increase seed yield. Having developed various crops, such as Camelina, canola, soybean, and corn, the firm concentrates to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter.

Executives

Jack W Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Richard William Hamilton	director	1535 RANCHO CONEJO BOULEVARD, THOUSAND OAKS CA 91320
Willie Loh	director	C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, WOBURN MA 01801
Charles B Haaser	officer: VP Fin and CAO
Lynne H Brum	officer: VP Planning and Comms	21 ERIE STREET, CAMBRIDGE MA 02139
Kristi Snell	officer: VP Research & CSO	C/O METABOLIX, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MA 01801
Anthony J Sinskey	director	C/O METABOLIX, 21 ERIE STREET, CAMBRIDGE MA 02139
Sherri M. Brown	director	C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MO 01801
Oliver P Peoples	director, officer: Pres & CEO	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Joseph H Shaulson	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Peter N Kellogg	director	MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Celeste Beeks Mastin	director	21 ERIE STREET, CAMBRIDGE MA 02139
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Matthew Strobeck	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
William P Scully	10 percent owner	C/O MCGRATH DOYLE & PHAIR, 150 BROADWAY, NEW YORK NY 10038